ClinicalTrials.gg
CompletedNCT00331864Updated Feb 18, 2011Results posted

SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3 interventional study of Ranibizumab in Age Related Macular Degeneration and Choroidal Neovascularization, sponsored by Novartis. Completed at 1 site in Switzerland. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-02-18.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
531
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
14th of 124
531 · median 64
Started
2006
with 7 others
Phase 3
31 of 125
2 open now
Registered
10th of 125
by date
Lead sponsor
7 of 125
Novartis

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 14th largest by enrollment of the 124 interventional ones that give a count, is one of 8 that started in 2006, is one of 31 in phase 3, and was the 10th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A. This study will assess the safety and efficacy of ranibizumab administered on an as-needed dosing regimen in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

03

Conditions studied

  • Age Related Macular Degeneration
  • Choroidal Neovascularization

Keywords

  • AMD, ranibizumab
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Patients who participated in this study included those who had completed participation in the study CRFB002A2301 (ANCHOR; NCT00061594), newly diagnosed patients, as well as previously diagnosed patients who had had recent disease progression.

Inclusion criteria

Inclusion Criteria:

  • Male or female patients > 50 years of age
  • Diagnosis of active primary or recurrent CNV secondary to AMD, including those with predominantly classic, minimally classic or occult lesions with no classic component
  • The total area of CNV (including both classic and occult components) encompassed within the lesion must be >= 50% of the total lesion area
  • The total lesion area must be \<= 12 disc areas
  • Patients who have a BCVA (best corrected visual acuity) score between 73 and 24 letters, inclusive, in the study eye using ETDRS-like (Early Treatment of Diabetic Retinopathy Study) grading charts (approximately 20/40 to 20/320)

Exclusion criteria

Exclusion Criteria:

  • Patients who have a BCVA of \< 34 letters in both eyes (legally blind is defined as bilateral vision below 20/200 or less than 34 letters)
  • Laser photocoagulation, treatment with intravitreal , verteporfin photo dynamic therapy or pegaptanib sodium in the study eye within 30 days preceding Day 1
  • Previous participation in a clinical trial (for either eye) involving anti-angiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase C inhibitors, etc.)

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
531 participants (actual)

Study arms

  • Experimental
    Ranibizumab

    Ranibizumab-naïve (Non-ANCHOR) patients received up to 12 intravitreal injections (Month 0 through Month 11). The dose of 0.3 mg ranibizumab was administered monthly for three consecutive months. From Month 3 through Month 11, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab were injected as individually needed based on re-treatment criteria described in the protocol. For patients who had participated in the ANCHOR study, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab was injected if the patient met re-treatment criteria described in the protocol. Ranibizumab was administered no sooner than 14 days after the previous treatment.

    Drug: Ranibizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With Ocular Adverse Events (AEs) in the Study Eye

    Percentage of patients with ocular adverse events in the study eye over the one year (12 month) treatment period.

    Time frame: Baseline through end of study (12 month treatment period)

  2. Percentage of Patients With Targeted Grade 3 Adverse Events (AEs) in the Study Eye

    Grade 3 targeted AEs included: * 4+ ocular inflammation or 2-3+ ocular inflammation failing to decrease to ≤ 1+ within 30 days * ≥ 30 letter decrease in BCVA that developed within 14 days of ranibizumab injection * sustained (\>15 minutes) loss of light perception due to elevated intraocular pressure (IOP) or a \>20 mm Hg change in IOP persisting longer than 14 days * new retinal tear or detachment involving the macula * new vitreous hemorrhage \>2+ severity not resolving within 14 days * new or increase of previous retinal hemorrhage \>1 disc area in size and involving the fovea

    Time frame: Baseline through end of study (12 month treatment period)

Secondary outcomes

  1. Mean Change in Best Corrected Visual Acuity (BCVA) of the Study Eye From Baseline to Month 3

    BCVA was assessed using best correction determined from protocol refraction. BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters. BCVA is measured by the number of letters a patient could correctly read on an eye chart; hence an increased score indicates improvement in acuity.

    Time frame: Baseline and Month 3

  2. Mean Change in Best Corrected Visual Acuity (BCVA) of the Study Eye From Baseline to Month 12

    BCVA was assessed using best correction determined from protocol refraction. BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters. BCVA is measured by the number of letters a patient could correctly read on an eye chart; hence an increased score indicates improvement in acuity.

    Time frame: Baseline and Month 12

  3. Mean Change in Central Retinal Thickness of the Study Eye From Baseline to Month 3

    Central retinal thickness was assessed using optical coherence tomography (OCT). OCT imaging was performed by trained personnel at each site using the Zeiss Stratus OCT™ 3 with version A6.1 (or more recent) software. Analysis of the OCT images was performed by the investigator. A negative number indicates improvement (reduced thickness).

    Time frame: Baseline and Month 3

  4. Mean Change in Central Retinal Thickness of the Study Eye From Baseline to Month 12

    Central retinal thickness was assessed using optical coherence tomography (OCT). OCT imaging was performed by trained personnel at each site using the Zeiss Stratus OCT™ 3 with version A6.1 (or more recent) software. Analysis of the OCT images was performed by the investigator. A negative number indicates improvement (reduced thickness).

    Time frame: Baseline and Month 12

  5. Time to the First Retreatment After Month 2

    Time to first re-treatment is calculated as time difference in months starting from Month 2 until the month of first re-treatment. Criteria for re-treatment: * a \>5 letter decrease in BCVA (determined using EDRS charts) based upon the highest visual acuity score from any prior scheduled study visit (Months 0, 1, 2 or 3) * a \>100 µm increase in central retinal thickness (determined using OCT) from the thinnest measurement from any prior scheduled study visit (Months 0, 1, 2 or 3)

    Time frame: Month 2 to Month 11

  6. Total Number of Treatments

    Total number of treatments administered during the entire treatment period (Month 0 to 11).

    Time frame: Baseline (Month 0) to Month 11

07

Results

Posted Jan 4, 2011

Participant flow

The study population consisted of two groups, one group being naïve to ranibizumab ("Non-ANCHOR" patients) and the other group were those patients who previously were treated with ranibizumab in the ANCHOR study (NCT00061594; "ANCHOR" patients).

Participant flow — Overall Study
MilestoneRanibizumab Non-ANCHORRanibizumab ANCHOR
Started51318
Completed45514
Not completed584
Withdrew: Adverse event301
Withdrew: Lack of efficacy40
Withdrew: Protocol violation30
Withdrew: Withdrawal by subject100
Withdrew: Lost to follow-up43
Withdrew: Administrative problems10
Withdrew: Death60

Outcome measures

PrimaryPercentage of Patients With Ocular Adverse Events (AEs) in the Study Eye

Percentage of patients with ocular adverse events in the study eye over the one year (12 month) treatment period.

Time frame:
Baseline through end of study (12 month treatment period)
Reported as:
Number · Percentage of Participants
Percentage of Patients With Ocular Adverse Events (AEs) in the Study Eye
Percentage of ParticipantsRanibizumab Non-ANCHORRanibizumab ANCHOR
Percentage of Patients With Ocular Adverse Events (AEs) in the Study Eye48.538.9
SecondaryMean Change in Best Corrected Visual Acuity (BCVA) of the Study Eye From Baseline to Month 3

BCVA was assessed using best correction determined from protocol refraction. BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters. BCVA is measured by the number of letters a patient could correctly read on an eye chart; hence an increased score indicates improvement in acuity.

Time frame:
Baseline and Month 3
Reported as:
Mean · Letters on the ETDRS-like testing charts
Mean Change in Best Corrected Visual Acuity (BCVA) of the Study Eye From Baseline to Month 3
Letters on the ETDRS-like testing chartsRanibizumab Non-ANCHORRanibizumab ANCHOR
Baseline56.2 ± 12.1147.2 ± 22.10
Change to Month 35.8 ± 11.121.9 ± 9.26
SecondaryMean Change in Best Corrected Visual Acuity (BCVA) of the Study Eye From Baseline to Month 12

BCVA was assessed using best correction determined from protocol refraction. BCVA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters. BCVA is measured by the number of letters a patient could correctly read on an eye chart; hence an increased score indicates improvement in acuity.

Time frame:
Baseline and Month 12
Reported as:
Mean · Letters on the ETDRS-like testing charts
Mean Change in Best Corrected Visual Acuity (BCVA) of the Study Eye From Baseline to Month 12
Letters on the ETDRS-like testing chartsRanibizumab Non-ANCHORRanibizumab ANCHOR
Baseline56.2 ± 12.1147.2 ± 22.10
Change to Month 123.6 ± 13.891.6 ± 8.66
SecondaryMean Change in Central Retinal Thickness of the Study Eye From Baseline to Month 3

Central retinal thickness was assessed using optical coherence tomography (OCT). OCT imaging was performed by trained personnel at each site using the Zeiss Stratus OCT™ 3 with version A6.1 (or more recent) software. Analysis of the OCT images was performed by the investigator. A negative number indicates improvement (reduced thickness).

Time frame:
Baseline and Month 3
Reported as:
Mean · Micrometers
Mean Change in Central Retinal Thickness of the Study Eye From Baseline to Month 3
MicrometersRanibizumab Non-ANCHORRanibizumab ANCHOR
Baseline339.6 ± 109.38214.1 ± 64.92
Change to Month 3-101.1 ± 115.6936.3 ± 72.96
SecondaryMean Change in Central Retinal Thickness of the Study Eye From Baseline to Month 12

Central retinal thickness was assessed using optical coherence tomography (OCT). OCT imaging was performed by trained personnel at each site using the Zeiss Stratus OCT™ 3 with version A6.1 (or more recent) software. Analysis of the OCT images was performed by the investigator. A negative number indicates improvement (reduced thickness).

Time frame:
Baseline and Month 12
Reported as:
Mean · Micrometers
Mean Change in Central Retinal Thickness of the Study Eye From Baseline to Month 12
MicrometersRanibizumab Non-ANCHORRanibizumab ANCHOR
Baseline339.6 ± 109.38214.1 ± 64.92
Change to Month 12-91.5 ± 115.4739.3 ± 84.61
SecondaryTime to the First Retreatment After Month 2

Time to first re-treatment is calculated as time difference in months starting from Month 2 until the month of first re-treatment. Criteria for re-treatment: * a \>5 letter decrease in BCVA (determined using EDRS charts) based upon the highest visual acuity score from any prior scheduled study visit (Months 0, 1, 2 or 3) * a \>100 µm increase in central retinal thickness (determined using OCT) from the thinnest measurement from any prior scheduled study visit (Months 0, 1, 2 or 3)

Time frame:
Month 2 to Month 11
Reported as:
Median · Months
Time to the First Retreatment After Month 2
MonthsRanibizumab Non-ANCHOR
Time to the First Retreatment After Month 22 (1 to 6)
SecondaryTotal Number of Treatments

Total number of treatments administered during the entire treatment period (Month 0 to 11).

Time frame:
Baseline (Month 0) to Month 11
Reported as:
Mean · Treatments
Total Number of Treatments
TreatmentsRanibizumab Non-ANCHORRanibizumab ANCHOR
Total Number of Treatments5.6 ± 2.371.1 ± 2.29
PrimaryPercentage of Patients With Targeted Grade 3 Adverse Events (AEs) in the Study Eye

Grade 3 targeted AEs included: * 4+ ocular inflammation or 2-3+ ocular inflammation failing to decrease to ≤ 1+ within 30 days * ≥ 30 letter decrease in BCVA that developed within 14 days of ranibizumab injection * sustained (\>15 minutes) loss of light perception due to elevated intraocular pressure (IOP) or a \>20 mm Hg change in IOP persisting longer than 14 days * new retinal tear or detachment involving the macula * new vitreous hemorrhage \>2+ severity not resolving within 14 days * new or increase of previous retinal hemorrhage \>1 disc area in size and involving the fovea

Time frame:
Baseline through end of study (12 month treatment period)
Reported as:
Number · Percentage of Participants
Percentage of Patients With Targeted Grade 3 Adverse Events (AEs) in the Study Eye
Percentage of ParticipantsRanibizumab Non-ANCHORRanibizumab ANCHOR
Percentage of Patients With Targeted Grade 3 Adverse Events (AEs) in the Study Eye2.90.0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab Non-ANCHOR—80/513 (15.6%)199/513 (38.8%)
Ranibizumab ANCHOR—4/18 (22.2%)8/18 (44.4%)
Most frequent serious events
Showing 10 of 117
Most frequent serious events
EventRanibizumab Non-ANCHORRanibizumab ANCHOR
AnaemiaBlood and lymphatic system disorders1/5131/18
Acute myocardial infarctionCardiac disorders1/5131/18
Atrial fibrillationCardiac disorders2/5131/18
FallInjury, poisoning and procedural complications0/5131/18
Humerus fractureInjury, poisoning and procedural complications0/5131/18
Pelvic fractureInjury, poisoning and procedural complications0/5131/18
Extranodal marginal zone B-cell lymphoma (MALT type)Neoplasms benign, malignant and unspecified (incl cysts and polyps)0/5131/18
Cerebrovascular accidentNervous system disorders1/5131/18
HypoaesthesiaNervous system disorders0/5131/18
Benign prostatic hyperplasiaReproductive system and breast disorders0/5131/18
Most frequent other events
Most frequent other events
EventRanibizumab Non-ANCHORRanibizumab ANCHOR
Retinal haemorrhage (Study eye)Eye disorders35/5135/18
Visual acuity reduced (Study eye)Eye disorders94/5131/18
Choroidal neovascularisation (Fellow eye)Eye disorders16/5132/18
Choroidal neovascularisation (Study eye)Eye disorders8/5132/18
Retinal haemorrhage (Fellow eye)Eye disorders12/5132/18
Retinal oedema (Study eye)Eye disorders8/5132/18
Intraocular pressure increased (Study eye)Investigations36/5130/18
Visual acuity reduced (Fellow eye)Eye disorders23/5131/18
HeadacheNervous system disorders13/5131/18
Conjunctival haemorrhage (Study eye)Eye disorders28/5130/18

Baseline characteristics

Age, Customized
Age, Customized(participants)Ranibizumab Non-ANCHORRanibizumab ANCHORTotal
< 50 years101
50 to < 65 years49049
65 to < 75 years1735178
75 to < 85 years23012242
≥ 85 years60161
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab Non-ANCHORRanibizumab ANCHORTotal
Female2949303
Male2199228
08

Study locations

1 site
  • Novartis - 64 sites in 11 countries
    Basel, Switzerland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2006
First posted
May 31, 2006
Start
Apr 2006
Primary completionActual
Apr 2008
Completion
Apr 2008
Results first posted
Jan 4, 2011
Last update
Feb 18, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00331864
Lead sponsor
Novartis
First posted
May 31, 2006
Start date
Apr 2006
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Jan 4, 2011
Last update
Feb 18, 2011

Study contacts

Novartis Customer Information
study chair · Novartis - Including Sites in Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion